ArticleScience advances2026
Integrating structurally defined DNA-carbon nanotube sensors with machine learning for cancer detection.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy is a promising, noninvasive approach for cancer detection, but current methods often trade off accuracy, operability, and cost. To address these limitations, we introduce an artificial perception system (APS) for liquid biopsy that combines a structurally defined DNA-carbon nanotube sensor array with machine learning (ML) models. The array produces multichannel fluorescence fingerprints from serum, which are decoded by ML models to classify disease state. In a total of 253 serum samples spanning liver, lung, and ovarian cancers and noncancer controls, the APS achieved mean sensitivity of 89% and specificity of 96%. Notably, early-stage lung cancer was detected with 92% sensitivity and 95% specificity at an estimated cost of ∼$4 USD per test. Insights from SHAP analysis and Mantel test revealed the detection mechanisms of APS, supporting biological plausibility and clinical translation. These results highlight a path toward accurate, scalable, and affordable multicancer detection and early cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.